Correspondence 0001104659-23-128380 from Applied Therapeutics, Inc. (APLT) (CIK 0001697532)

Applied Therapeutics, Inc. (APLT) (CIK 0001697532)
Date: Dec. 21, 2023 · CIK: 0001697532 · Accession: 0001104659-23-128380

View on Edgar

AI Filing Summary & Sentiment

File numbers found in text: 001-38898

Referenced dates: December 7, 2023

Date

December 21, 2023

Author

/s/ Michael J. Schwartz

Form

CORRESP

Company

Applied Therapeutics, Inc. (APLT) (CIK 0001697532)

Letter

Division of Corporate Finance Office of Life Sciences Filed March 23, 2023 Form 10-Q for the Nine Months Ended September 30, Filed November 9, 2023 File No. 001-38898

Dear Ms. Mast and Mr. Gordon:

Applied Therapeutics Inc. (the “Company”) confirms that it has received the letter dated December 7, 2023 (the “Comment Letter”) from the staff (the “Staff”) of the Securities and Exchange Commission with respect to the above-referenced Forms 10-K and 10-Q. The Company respectfully requests an extension and expects to respond to the comments in the Comment Letter on or before Friday, January 12, 2024.

Please contact Michael J. Schwartz at (212) 735-3694 or Michael.Schwartz@skadden.com if the Staff has any questions or requires additional information.

Very truly yours,
/s/ Michael J. Schwartz

Show Raw Text

CORRESP
1
filename1.htm

December 21, 2023

BY EDGAR

Division of Corporate Finance

Office of Life Sciences

U.S. Securities and Exchange Commission

100 F Street, N.E.

Washington, DC 20549

Attn: Mary
Mast

Daniel Gordon

 Re: Applied Therapeutics Inc.

Form 10-K for the Fiscal Year Ended December 31,
2022

Filed March 23, 2023

Form 10-Q for the Nine Months Ended September 30,
2023

Filed November 9, 2023

File No. 001-38898

Dear Ms. Mast and Mr. Gordon:

Applied Therapeutics Inc. (the “Company”)
confirms that it has received the letter dated December 7, 2023 (the “Comment Letter”) from the staff (the “Staff”)
of the Securities and Exchange Commission with respect to the above-referenced Forms 10-K and 10-Q. The Company respectfully requests
an extension and expects to respond to the comments in the Comment Letter on or before Friday, January 12, 2024.

Please contact Michael J. Schwartz at (212) 735-3694
or Michael.Schwartz@skadden.com if the Staff has any questions or requires additional information.

  Very truly yours,

  /s/ Michael J. Schwartz

cc: Shoshana Shendelman, Applied Therapeutics
Inc.

Michael J. Schwartz, Skadden, Arps, Slate, Meagher &
Flom LLP

SecProbe.io